Intraocular Injection Of Bevacizumab Research Articles

Intraocular bevacizumab for iris neovascularization in a silicone oil-filled eye.

To report the effectiveness of intravitreal injection of bevacizumab for treatment of iris neovascularization in a silicone oil-filled eye. Case report. A 56-year-old man with recurrent retinal detachment associated with iris neovascularization. Iris neovascularization regressed after treatment with a 1.25-mg intravitreal injection of bevacizumab in the presence of silicone oil. Intraocular injection of bevacizumab is an effective short-term treatment of neovascularization caused by persistent retinal detachment even in the presence of silicone oil. The standard dose of 1.25 mg of bevacizumab may not require adjustment in an aphakic vitrectomized eye.

Intracameral Bevacizumab for Iris Rubeosis

To determine whether intracameral bevacizumab decreases vascular leakage from iris rubeosis in patients with neovascular glaucoma. Interventional case series. The study included six eyes of three patients with secondary neovascular glaucoma due to proliferative diabetic retinopathy (n = 2) or ischemic central retinal vein occlusion (n = 1). All patients received an intracameral injection of 1.0 mg bevacizumab. Morphologic changes and vascular leakage were investigated prospectively by iris fluorescein angiography. Decrease in leakage was detected as early as one day after injection. No inflammation was observed. No relapse was seen within the follow-up of four weeks. Intraocular injection of bevacizumab may provide an additional strategy for the treatment of iris rubeosis in neovascular glaucoma.